JP2020201068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020201068A5 JP2020201068A5 JP2019106792A JP2019106792A JP2020201068A5 JP 2020201068 A5 JP2020201068 A5 JP 2020201068A5 JP 2019106792 A JP2019106792 A JP 2019106792A JP 2019106792 A JP2019106792 A JP 2019106792A JP 2020201068 A5 JP2020201068 A5 JP 2020201068A5
- Authority
- JP
- Japan
- Prior art keywords
- atp
- hypoxanthine
- patient
- therapeutic effect
- enhancing therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 229940122272 Oxidoreductase inhibitor Drugs 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 claims 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 claims 1
- 108010093894 Xanthine oxidase Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000002457 oxidoreductase inhibitor Substances 0.000 claims 1
- 230000002123 temporal effect Effects 0.000 claims 1
Claims (5)
ＡＴＰ増強療法を施す前の患者由来サンプル中のヒポキサンチン（hypoxanthine）を測定
する工程と、
当該ヒポキサンチン（hypoxanthine）測定値にもとづき、これから行われるＡＴＰ増強療
法の治療効果を判定する工程と、
を含む前記治療効果の予測方法。 A method for predicting the therapeutic effect of ATP-enhancing therapy for neurodegenerative diseases.
The process of measuring hypoxanthine in patient-derived samples prior to ATP-enhancing therapy, and
The process of determining the therapeutic effect of the ATP-enhancing therapy to be performed based on the measured value of hypoxanthine, and
The method for predicting the therapeutic effect including.
求項１に記載の予測方法。 The prediction method according to claim 1, wherein the patient-derived sample is a patient's blood-derived sample and / or cerebrospinal fluid-derived sample.
工程が、
当該ヒポキサンチン（hypoxanthine）測定値を所定の数値と比較して、
当該ヒポキサンチン（hypoxanthine）測定値が所定の数値よりも低い場合にこれから行わ
れるＡＴＰ増強療法が有効である可能性が高いと示される工程である請求項１又は２に記
載の予測方法。 The process of predicting the therapeutic effect of the ATP-enhancing therapy to be performed based on the measured value of the hypoxane is
Comparing the hypoxanthine measurement value with the predetermined value,
The prediction method according to claim 1 or 2, which is a step indicating that the ATP enhancing therapy to be performed is likely to be effective when the measured value of hypoxanthine is lower than a predetermined value.
に投与する工程を含む治療法である、請求項１～３のいずれかに記載の予測方法。
（Ａ）キサンチン酸化還元酵素阻害剤
（Ｂ）ヒポキサンチン（hypoxanthine）、または体内でヒポキサンチン（hypoxanthine）
に変換され得る化合物 The prediction method according to any one of claims 1 to 3 , wherein the ATP-enhancing therapy is a treatment method comprising the step of administering to a patient an ATP-enhancing agent containing the following (A) and / or (B) as an active ingredient. ..
(A) Xanthine oxidoreductase inhibitor (B) Hypoxanthine, or hypoxanthine in the body
Compounds that can be converted to
ー小体型認知症、前頭側頭型認知症、多発性硬化症、又は筋萎縮性側索硬化症およびハン
チントン病かならる群から選ばれる１以上である請求項１～４のいずれかに記載の予測方
法。 From the group in which the neurodegenerative disease is Parkinson's disease, Parkinson's syndrome, Alzheimer's dementia, Lewy body dementia, frontal temporal dementia, multiple sclerosis, or amyotrophic lateral sclerosis and Huntington's disease. The prediction method according to any one of claims 1 to 4, which is one or more selected.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019106792A JP7333942B2 (en) | 2019-06-07 | 2019-06-07 | Method for predicting effect of ATP-enhancing therapy on neurodegenerative disease |
| KR1020217043096A KR20220018512A (en) | 2019-06-07 | 2020-06-05 | How to predict the effectiveness of ATP-enhancing therapy for neurodegenerative diseases |
| PCT/JP2020/022219 WO2020246564A1 (en) | 2019-06-07 | 2020-06-05 | Method for predicting results of atp augmentation treatment for neurodegenerative disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019106792A JP7333942B2 (en) | 2019-06-07 | 2019-06-07 | Method for predicting effect of ATP-enhancing therapy on neurodegenerative disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020201068A JP2020201068A (en) | 2020-12-17 |
| JP2020201068A5 true JP2020201068A5 (en) | 2022-06-10 |
| JP7333942B2 JP7333942B2 (en) | 2023-08-28 |
Family
ID=73652238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019106792A Active JP7333942B2 (en) | 2019-06-07 | 2019-06-07 | Method for predicting effect of ATP-enhancing therapy on neurodegenerative disease |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP7333942B2 (en) |
| KR (1) | KR20220018512A (en) |
| WO (1) | WO2020246564A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69934987T2 (en) * | 1998-07-31 | 2007-05-16 | Sacks, Meir S. | A PRESCRIBER OF HARMIC ACID AND A COMPOSITION CONTAINING ANTIOXIDANT AND THEIR USE FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| JP6875683B2 (en) * | 2015-05-19 | 2021-05-26 | 国立研究開発法人国立精神・神経医療研究センター | How to determine the application of new treatment for multiple sclerosis (MS) patients |
| JP6153281B1 (en) | 2015-08-26 | 2017-06-28 | 株式会社スタージェン | Intracellular ATP enhancer |
| IT201600109735A1 (en) * | 2016-10-31 | 2018-05-01 | Giuseppe Lazzarino | Biomarkers and methods for in vitro diagnosis of multiple sclerosis. |
| JP6937134B2 (en) * | 2016-11-21 | 2021-09-22 | 株式会社スタージェン | Intracellular ATP enhancer |
| WO2018092911A1 (en) | 2016-11-21 | 2018-05-24 | 株式会社スタージェン | Intracellular atp enhancer |
| JP6966840B2 (en) * | 2017-01-24 | 2021-11-17 | 株式会社スタージェン | Drugs for improving neurodegenerative diseases |
-
2019
- 2019-06-07 JP JP2019106792A patent/JP7333942B2/en active Active
-
2020
- 2020-06-05 WO PCT/JP2020/022219 patent/WO2020246564A1/en active Application Filing
- 2020-06-05 KR KR1020217043096A patent/KR20220018512A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kihara et al. | α7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A β-amyloid-induced neurotoxicity | |
| Veitinger et al. | Platelets, a reliable source for peripheral Alzheimer’s disease biomarkers? | |
| Kellogg 3rd et al. | Cellular senescence in idiopathic pulmonary fibrosis | |
| Fischer | Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue? | |
| Holland et al. | Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque | |
| MA34828B1 (en) | METHODS AND MEDICAMENT PRODUCTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| CN114822876B (en) | Predictive model, device and storage medium for drug absorption rate constant | |
| EA201800499A1 (en) | THYROZINKINASE INHIBITOR FOR THE TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS, COMPOSITION, MEDICINE, SET | |
| Bansi et al. | Persons with secondary progressive and relapsing remitting multiple sclerosis reveal different responses of tryptophan metabolism to acute endurance exercise and training | |
| JP2007502630A5 (en) | ||
| Lauretti et al. | Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson’s disease | |
| JP2014534197A5 (en) | ||
| Wu et al. | Histone deacetylase inhibitor MS-275 alleviates postoperative cognitive dysfunction in rats by inhibiting hippocampal neuroinflammation | |
| JP2015505245A5 (en) | ||
| MA46268A (en) | 5- [2- (PYRIDIN-2-YLAMINO) -1,3-THIAZOL-5-YL] -2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND THEIR USE AS DOUBLE PHOSPHATIDYLINOSITOL INHIBITORS 3-KINASE DELTA & GAMMA | |
| JP2020201068A5 (en) | ||
| Lazarova et al. | Effects of new galantamine derivatives in a scopolamine model of dementia in mice | |
| Murai et al. | Relationship between serotonin transporter occupancies and analgesic effects of AS1069562, the (+)-isomer of indeloxazine, and duloxetine in reserpine-induced myalgia rats | |
| Lee et al. | High-fat diet and voluntary chronic aerobic exercise recover altered levels of aging-related tryptophan metabolites along the kynurenine pathway | |
| JP2020007333A5 (en) | ||
| Li et al. | PET imaging of adenosine receptors in diseases | |
| HUP0302938A2 (en) | Sgk2 and sgk3 used as diagnostic and therapeutic targets | |
| JPWO2019213612A5 (en) | ||
| Zhou et al. | Evaluation of therapeutic effect and cytokine change during transplacental Digoxin treatment for fetal heart failure associated with fetal tachycardia, a case–control study | |
| Mansouri et al. | Analysis of risk factors for psoriasis recurrence using proportional rates model |